risperidone has been researched along with Developmental Psychomotor Disorders in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 9.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 9.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 5.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 5.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "promazine in the treatment of behavioral and psychological symptoms in dementia(BPSD)." | 2.71 | Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). ( Cotroneo, A; De Sarro, G; Gareri, P; Lacava, R; Loiacono, A; Marigliano, N; Seminara, G, 2004) |
| " The failure to confirm previous claims of greater improvement on either risperidone or olanzapine in patients with a first episode of psychosis may be the result of methodological bias introduced by unequal dosing between the two drugs or the use of chronically ill and treatment-refractory patients in previous studies." | 2.71 | A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. ( Haricharan, R; Malla, A; Manchanda, R; Norman, R; Scholten, D; Takhar, J; Townsend, L, 2004) |
| "Probably pseudohypoaldosteronism was a coincidental finding in this girl with a CDK13 mutation, but because only limited information is known about CDK13-related disorders, further investigation could be more informative to clarify this presentation." | 2.61 | One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature. ( Ayman, A; Kremer, AK; van den Akker, M; Yakubov, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yakubov, R | 1 |
| Ayman, A | 1 |
| Kremer, AK | 1 |
| van den Akker, M | 1 |
| Ritchie, CW | 1 |
| Chiu, E | 1 |
| Harrigan, S | 1 |
| Hall, K | 1 |
| Hassett, A | 1 |
| Macfarlane, S | 1 |
| Mastwyk, M | 1 |
| O'Connor, DW | 1 |
| Opie, J | 1 |
| Ames, D | 1 |
| Gareri, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Seminara, G | 1 |
| Marigliano, N | 1 |
| Loiacono, A | 1 |
| De Sarro, G | 1 |
| Soyka, M | 1 |
| Winter, C | 1 |
| Kagerer, S | 1 |
| Brunnauer, M | 1 |
| Laux, G | 1 |
| Möller, HJ | 1 |
| Malla, A | 1 |
| Norman, R | 1 |
| Scholten, D | 1 |
| Townsend, L | 1 |
| Manchanda, R | 1 |
| Takhar, J | 1 |
| Haricharan, R | 1 |
| Pandina, GJ | 1 |
| Bossie, CA | 1 |
| Youssef, E | 1 |
| Zhu, Y | 1 |
| Dunbar, F | 1 |
| Heinz, A | 1 |
| Knable, MB | 1 |
| Coppola, R | 1 |
| Gorey, JG | 1 |
| Jones, DW | 1 |
| Lee, KS | 1 |
| Weinberger, DR | 1 |
1 review available for risperidone and Developmental Psychomotor Disorders
| Article | Year |
|---|---|
One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.
Topics: CDC2 Protein Kinase; Chelating Agents; DNA Mutational Analysis; Female; Humans; Infant; Intellectual | 2019 |
5 trials available for risperidone and Developmental Psychomotor Disorders
| Article | Year |
|---|---|
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O | 2003 |
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Brain; Diagnostic | 2004 |
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Topics: Adult; Antipsychotic Agents; Attention; Automobile Driving; Case-Control Studies; Female; Haloperido | 2005 |
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Female; Human | 2007 |
1 other study available for risperidone and Developmental Psychomotor Disorders
| Article | Year |
|---|---|
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Hu | 1998 |